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Protecting travellers against malaria is increasingly
important as the number travelling overseas continues
to rise, with a disproportionate increase in visits to
tropical areas where malaria transmission may occur.
Each year about 1700 cases of malaria occur in the
United Kingdom, 1300 in the United States, and 3000
in France.1-3 In the UK, about 75% of these cases are
caused by Plasmodium falciparum, which produces the
most severe form of malaria; five to 16 deaths occur
annually and are nearly always in cases of falciparum
malaria.1
Most infections occur in travellers resident in the
UK, rather than in visitors to theUK.Malaria is amajor
risk for travellers if they do not take chemoprophylaxis
or if they take incorrect prophylaxis.4 5 This review
explores how to protect travellers from malaria. Most
of the evidence base for malaria prophylaxis comes
from small randomised controlled trials or observa-
tional studies.
Approach to preventing malaria
A useful approach is the “ABCD” of malaria preven-
tion: Awareness of risk, Bite avoidance, Compliance
with chemoprophylaxis, and the prompt Diagnosis of
malaria (box 1).
Who is at risk and how does one assess it?
Factors determining individual risk
A detailed itinerary is necessary to assess risk. The
degree of transmission varies markedly between
different regions, evenwithinacountry, andatdifferent
times of the year. For example, the risk of acquiring
malaria in West Africa may reach 6% per month of
travel but on the Kenyan coast is 1% per month; in the
Kenyan capital, Nairobi, transmission is extremely
low.
In addition to geographical factors, an individual’s
risk depends on the time spent in the endemic area and
activities undertaken: camping in a jungle for three
weeks poses amuch higher risk than a three day visit to
an urban area with air conditioned accommodation.
Fourmain species ofmalaria parasites infect humans
after the bite of an infected Anopheles spp mosquito: P
falciparum, P vivax, P ovale and P malariae. P falciparum
and P vivax are the most common. Falciparummalaria
predominates in sub-SaharanAfrica, andvivaxmalaria
in the Indian subcontinent, Mexico, Central America,
and China; both species occur in South East Asia and
South America.
Groups at particular risk
Less than half of travellers who acquire malaria have
taken advice before travelling. Analysis of imported
malaria indicates that certain groups are at particular
risk, such as those taking lastminute holidays and those
visiting friends and relatives abroad.7 Travellers
visiting friends and relatives abroad (also known as
VFR travellers) account for 70% of all of the malaria
imported into the UK1; limited evidence suggests that
these travellers do not think of malaria as a serious or
potentially fatal disease, are less likely to consult
general practitioners or travel medicine specialists,
and often travel to areas of high risk such as West
Africa.7 8 Using intervention strategies for travellers
visiting friends and relatives—such as increasing
awareness in the community, dispelling myths about
immunity or subsidising antimalarials—could consid-
erably reduce imported malaria.9
How can bites be prevented?
Avoiding mosquito bites is critical. This will also help
to prevent other vector borne diseases such as yellow
fever or dengue. The peak time formalariamosquitoes
to bite is from dusk to dawn; during these times, using
repellents and covering up with clothing impregnated
with permethrin will help to prevent bites.10 Evidence
from trials is strong that sleeping under impregnated
bednets reduces the risk of malaria in endemic
populations, and this is likely to be equally effective in
travellers.11 All travellers should be advised to carry
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longlife impregnated nets. Several repellents are
effective (box 2). The chemical DEET has been most
thoroughly studied and is simplest to use as it needs
only infrequent reapplication.12 It is safe in children
aged over 2 months and in pregnant women.6 13 Most
“natural” repellents have a limited duration of activity,
and several popular measures are ineffective (box 3).
How do antimalarials work?
Allmalarial parasites develop in the liver after injection
of sporozoites by the mosquito. After a minimum
period of seven days,merozoites emerge from the liver
and infect red blood cells, causing clinical symptoms of
malaria. Infection with P vivax and P ovale may cause
persistent liver forms (hypnozoites) that re-emerge
months after initial infection. Most antimalarial drugs
kill parasites when they are in the red blood cells rather
than in the liver.14
How to choose a drug regimen
The choice of an effective drug for prophylaxis
depends on (a) individual factors, such as health
problems or medications (and whether medical
resources are available at the destination), length of
stay, and previous experience with antimalarials; and
(b) the region visited, which defines the predominant
malaria species and drug sensitivity (box 4). The
benefits and drawbacks of each medication, including
cost, should be thoroughly discussed with the traveller
(table).
The fivemain antimalarial regimens are chloroquine
alone, chloroquine plus proguanil, atovaquone plus
proguanil (Malarone), doxycycline, and mefloquine.
Resistance of P falciparum to chloroquine (and to a
lesser extent to other antimalarials) is a global problem,
and chloroquine now has limited effectiveness in most
of the world.
Areas where P falciparum is resistant to chloroquine
Three main drug options exist for prevention in the
areas where P falciparum is resistant to chloroquine:
atovaquone plus proguanil, doxycycline, and meflo-
quine. Some countries (such as the UK) also advocate
chloroquine plus proguanil for the limited areas of low
level resistance, such as parts of India and Indonesia.
Randomised controlled trials show that the three main
options all have similar efficacy (close to 90%) againstP
falciparum.15 16 Mefloquine should not be used for the
limited areas of multidrug resistance, such as the rural,
forested areas where Thailand has borders with
Cambodia and Burma.14
Travellers must continue prophylactic regimens
(except atovaquone plus proguanil) for four weeks
Box 1 Harm-benefit assessment based on the “ABCD” approach tomalaria prevention*
Assessment and awareness of malaria risk
 Detailedgeographical locationof trip (nameof countryalonenotadequate); timeof year
may also be relevant. See www.nathnac.org or www.cdc.gov/malaria/travel/index.htm
 Duration of time in the area
 Activities to be undertaken (relates to likelihood of exposure to infected mosquitoes—
urban environment is generally less risky than rural environment)
Bite avoidance
 Protective clothing
 Repellents
 Longlife insecticide-treated netting
Chemoprophylaxis
 Is chemoprophylaxis indicated or would bite avoidance be sufficient?
 Does the area have chloroquine resistant P falciparum?
 Consider medical history and other medications
 Consider previous experience with antimalarials
 Are there contraindications tomefloquine (history of psychiatric problems or epilepsy)?
 Take patient choice and resources into consideration when making decision
Diagnosis
 Consider diagnosis of malaria in travellers returning from endemic area
 Arrange prompt diagnostic tests (malaria slides or rapid diagnostic tests)
*Detailed templates available6
Box 2 Effective repellents
 DEET 20-50% gives 6-12 hours of protection (no
advantage from concentrations higher than 50%)12
 Picaridin 20% (relatively limited availability in the UK)
has a similar duration of protection to 20% DEET
 Lemon eucalyptus oil is effective, but needs frequent
reapplications
No malaria reported
No chloroquine resistance
Chloroquine resistance
Chloroquine and
mefloquine resistance
Malaria transmission and drug sensitivity across the world. Adapted from Canada Communicable
Disease Report. Vol 30S1. Health Canada, 2004
Box 3 Popular but ineffectivemalaria prevention practices
 Homoeopathic prophylaxis (deaths reported)
 Yeast, garlic, marmite, vitamin B-1
 Electronic mosquito repellents
 Some natural repellents, such as oil of citronella
(effective for only 30-60minutes, and reapplication is
needed too frequently for citronella to be
recommended12)
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after leaving the risk area as the drugs work by killing
parasites during theirdevelopment in the redbloodcells
(suppressive prophylaxis). The combination of atova-
quone plus proguanil prevents the development of liver
forms (causal prophylaxis) and therefore needs to be
taken only for a week after leaving the risk area,making
it ideal for short trips. However, atovaquone/proguanil
is considerably more expensive than the other
prophylactic regimens. P vivax and P ovale may persist
as hypnozoites in the liver, and therefore infection may
re-emerge many months after return (relapse) despite
compliance with chemoprophylaxis.16
Areas where malaria is sensitive to chloroquine
OnlyMexicoandpartsofCentralAmerica (areasnorth
andwest of the PanamaCanal), of theCaribbean (Haiti
and the Dominican Republic), of the Middle East, of
North Africa, and of China have malaria sensitive to
chloroquine (figure). Chloroquine or exceptionally
proguanil may be used in these regions.
Adverse events
In randomised controlled trials of the tolerability of
antimalarials, many patients report adverse events.
However, the rate of adverse events is also high in
placebo arms, making assessment of relation to the
drug difficult.17 Discontinuation of prophylaxis is less
than 5% for all drugs in most studies.17 18 Mild to
moderate neuropsychiatric problems (headache or
sleep disorder) are most common with mefloquine,
particularly in women. The frequency of severe
neuropsychiatric adverse reactions with mefloquine
remains controversial, with best estimates of a
frequency between 1 in 6000 to 1 in 20 000.19 Potential
adverse events with mefloquine should be discussed
with all travellers, and the drug should not be given to
those with neuropsychiatric disorders. The table out-
lines the adverse events associated with each of the
antimalarial agents.
Adherence
Adherence to chemoprophylaxis is a key component
of success in preventing malaria. The occurrence of
malaria in travellers who have returned home is almost
always associated with the failure to take any chemo-
prophylaxis, taking incorrect chemoprophylaxis, or
not complying with the drug regimen.1 Travellers
should bemade aware of the importance of completing
the course of antimalarials.
Are there new developments on the horizon?
Other drugs
Primaquine has been used for treating hypnozoites of P
vivax and P ovale for more than 50 years. Randomised
controlled trials havealso shown its efficacyas a “causal
prophylactic” and in preventing establishment of
hypnozoites.20 In the US, primaquine has recently
been recommended as second line prophylaxis. How-
ever, it is contraindicated in those with glucose-6-
phosphate dehydrogenase (G6PD) deficiency, and this
enzymemust be checked before the drug is prescribed.
Although not currently recommended in the UK,
primaquine may be useful for short trips in travellers
who have contraindications to other antimalarials.
Tafenoquine has similar properties to primaquine
and has been shown to be effective in randomised
controlled trials.21 It may be given in monthly or
weekly doses and is well tolerated in individuals with a
normal glucose-6-phosphate dehydrogenase level but
is not yet licensed or released.
Characteristics of different antimalarial drugs
Drug Adverse events Resistance Other considerations
Chloroquine Nausea; gastrointestinal symptoms; retinal
toxicity with high cumulative dose*
Widespread (especially sub-
Saharan Africa, South East
Asia)
Available over counter; weekly dose;
cheap
Proguanil Gastrointestinal symptoms; mouth ulcers when
combined with chloroquine
Widespread (especially sub-
Saharan Africa)
Available over counter; daily dose;
cheap
Mefloquine Neuropsychiatric problems Areas of Thailand that share
borders with Burma, Laos,
and Cambodia
Private prescription only; weekly
dose
Doxycycline Oesophageal symptoms; photosensitivity;
vaginal yeast infections
Minimal Private prescription only;
daily dose
Atovaquone plus proguanil
(Malarone)
Gastrointestinal symptoms; rash Sporadic case reports only Private prescription only; ideal for
short trips; daily dose; expensive
Primaquine Haemolysis in individuals with glucose-6-
phosphate dehydrogenase deficiency;
gastrointestinal symptoms
For eradication of P vivax
30mg (base) daily is needed
Second line choice; private
prescription only; ideal for short
trips; daily dose
*Do ophthalmological examinations every 6-12 months after 5-6 years’ continuous use.
Box 4 Antimalarial regimens
All regions
 Atovaquone plus proguanil (Malarone)
 Doxycycline
 Mefloquine
Regions with limited chloroquine resistance
 Chloroquine plus proguanil
Regions with chloroquine sensitivity
 Chloroquine
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Malaria vaccine
A wholly protective vaccine for travellers will not be
available in the near future. Considerable funding and
researchhave led to a sporozoite based vaccine that has
shown partial protection in African children. Never-
theless, awareness, bite prevention, and chemo-
prophylaxis will remain the mainstay of prevention
for some time.
Are there alternative strategies to chemoprophylaxis?
Some countries, including Germany and Switzerland,
recommend that when the risk of malaria is relatively
low, travellers should not take chemoprophylaxis
but should carry antimalarials, to be taken if they
develop a fever (“standby” treatment).19 Although this
approach has the advantage of avoiding potential
adverse effects of chemoprophylaxis, observational
evidence shows that standby antimalarials are often
taken inappropriately.22 The availability of rapid self
diagnosismalaria tests has not proved helpful either, as
observational studies have shown that sick individuals
often have difficulty performing the tests accurately.23
Current UK recommendations therefore do not
support this approach.
What can be done for the “complex” traveller?
Pregnancy and breast feeding
Pregnant women have an increased risk of contracting
malaria and of developing severe illness. If possible,
they should be dissuaded from visiting risk areas.
Extensive clinical experience shows that chloroquine
and proguanil (with additional folate) are safe, but this
combination has limited efficacy in areas where P
falciparum is resistant to chloroquine. Doxycycline is
contraindicated owing to its effects on skeletal devel-
opment, and there are insufficient data (although no
theoretical risk) for atovaquone plus proguanil. Some
evidence supports the safety of mefloquine in the
second and third trimesters, and it therefore remains
the drug of choice for chloroquine resistance areas.6 24
Caution is neededwithmefloquine in the first trimester
because of limited data. DEET seems to be safe in
pregnancy.13 Impregnated nets may be particularly
useful for pregnant mothers.
Data are limited on the excretion of antimalarials in
breast milk. Drugs that are contraindicated in preg-
nancy should not be taken if the mother is breast
feeding. The amount of drug excreted in breast milk is
insufficient toprotect the infant, so separatemedication
is needed for the infant. Caution is needed with
children at the lowest end of the weight band when
both mother and child are taking mefloquine.
Children
Apart from doxycycline, all drugs can be used in
childrenover10kg.Chloroquineplusproguanil canbe
used from birth, and mefloquine can be prescribed in
those over 5 kg.6 Impregnated netsmay be particularly
useful for children.
Long term travellers
Long term travellers (those spending six months or
more overseas) need a preventive strategy with a well
tolerated regimen that will be followed consistently.25
Although fewantimalarials are licensed formore thana
year, this reflects a lack of controlled studies on long
term use rather than evidence of harm. Knowing the
epidemiological pattern of malaria and the degree of
risk is also helpful in matching prevention to an
individual. Continuous use of chloroquine for more
than five years should be accompanied by ophthalmo-
logical screening.
What about when the traveller returns home?
Malariaprophylaxis is not100%effective evenwith full
adherence. All travellers and health professionals
should consider the possibility of malaria if fever
develops after travelling in a malaria endemic zone.
Observational data show that most falciparummalaria
will present within the first three months of return, but
vivax malaria and ovale malaria can present much
later. A malaria slide should always be obtained in a
febrile patient who has visited a risk area, even if the
symptoms suggest another cause.26
If a patient presents with an adverse reaction to an
antimalarial after returning home, consider whether to
switch antimalarials or discontinue them. Expert
opinion suggests that in most circumstances, particu-
larly if the patient is unwell, it is appropriate to stop
prophylaxis and warn the patient that they have had
ADDITIONAL EDUCATIONAL RESOURCES
 National Travel Health Network and Centre (www.
nathnac.org)—General travel advice and detailed
country recommendations and maps (for health
professionals and travellers)
 Fit For Travel (www.fitfortravel.scot.nhs.uk)—General
guidance for travellers
 Health Protection Agency’s malaria prevention
guidelines (www.hpa.org.uk/infections/topics_az/
malaria/guidelines.htm)—Highly detailed
recommendations of all aspects ofmalaria prevention
(for health professionals)
 Centers for Disease Control and Prevention’s
recommendations (www.cdc.gov/malaria/travel/
index.htm)— General guidance (for health
professionals and travellers)
 World Health Organization: International Travel And
Health (www.who.int/ith/en/index.html)—General
guidance (for health professionals and travellers)
QUESTIONS FOR FUTURE RESEARCH
 How to engage those who are visiting friends and
relatives
 New agents for antimalarial prophylaxis
 Role of standby treatment in areas of lower risk
 Safety of antimalarials in pregnancy
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inadequate prophylaxis and should therefore report
fevers immediately.
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SUMMARY POINTS
Malaria can be prevented by avoiding bites and using
appropriate chemoprophylaxis
An individual harm-benefit assessment should bemade for
each traveller
The possibility of malaria should be kept in mind for any
traveller returning from an endemic area
I need my medicine to help me get worse
While on a recent placement in general practice, I saw a
man with chronic obstructive pulmonary disease who had
come in to pick up a repeat prescription for his inhalers.
Dutifully followingNICEguidance on themanagement of
stable chronic obstructive pulmonary disease, I took the
opportunity to ask about smoking cessation.
“I haven’t smoked for five days,” came the reply.
“Excellent,” I thought, “he’s made the first step towards
packing up, and, with extra encouragement and some
nicotine replacement therapy, maybe we can keep him on
the straight and narrow.”
However, further questioning about his motivation for
stopping uncovered the reality of the situation: “Actually,
my inhalers ran out five days ago, and my breathing has
been so bad that I can’t smoke—so I need some more
inhalers.”
When I asked whether there was anything that would
make him consider giving up permanently, “Stopping my
inhalers” was his only contribution. Optimism turned to
indecision:was thepriority to help himgiveup smokingor
to treat the symptoms of the disease that smoking had
caused?The “correct” course of actionwasn’t given by the
guidance. Time to defer to my GP tutor.
As the GP handed over a prescription for the inhalers at
the end of the consultation, I felt it was an unavoidable,
albeit unsatisfactory outcome. We might as well have
given him a prescription for some cigarettes—and I’m
fairly sure that’s not part of the NICE guidance.
David Agombar fifth year medical student
University of Birmingham, Birmingham
dea418@bham.ac.uk
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